VIR4:05 PMVir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Resultsvir.bio
VIR4:05 PMVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directorsvir.bio
VIR4:05 PMVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026Presentation / Abstract • Phase 2vir.bio